Author + information
- R. Preston Mason and
- Samuel C.R. Sherratt
Eicosapentaenoic acid (EPA) reduces oxidation of ApoB-containing particles in vitro and in patients with hypertriglyceridemia. EPA may produce these effects through an antioxidant mechanism which may extend to membrane lipids at therapeutic concentrations. The plasma concentration of EPA is in the micromolar range at a pharmacologic dose of 4 g/day.
Iodometric approaches were used to measure lipid hydroperoxide (LOOH) formation in membrane vesicles (cholesterol and dilinoleoylphosphatidylcholine). Vesicles were prepared at a cholesterol-to-phospholipid mole ratio of 0.6:1. Lipid oxidation was stimulated with 10 µM copper sulfate. The antioxidant activity of EPA was tested over a range of concentrations (1.0 to 10.0 µM).
EPA inhibited membrane lipid oxidation in a highly dose-dependent manner. After four hours, EPA significantly inhibited LOOH formation starting at 1.0 µM (6%, p<0.05) and increased to 74% (p<0.001) at the maximum concentration. The half-maximum concentration of LOOH inhibition was ~6 µM.
These data support a concentration-dependent antioxidant effect for EPA in a pure formulation and at pharmacologic concentrations. As membrane lipid oxidation is an important contributor to atherosclerosis, the inhibition of oxidation by EPA at an appropriate high dose and concentration may provide a potential mechanism for reduced cardiovascular risk.
Poster Hall, Hall F
Saturday, March 16, 2019, 3:45 p.m.-4:30 p.m.
Session Title: Vascular Medicine: Basic 2
Abstract Category: 38. Vascular Medicine: Basic
Presentation Number: 1180-452
- 2019 American College of Cardiology Foundation